## Pathophysiology Bronchiectasis represents a chronic, progressive respiratory disorder characterized by the permanent and irreversible dilation of the bronchial walls. This structural damage is primarily the result of a "vicious cycle" of events—a concept originally proposed by Cole. The cycle begins with an initial insult, such as an infection, severe childhood respiratory insult, or an underlying genetic defect, which impairs the mucociliary clearance mechanism. This impairment leads to the stasis of secretions and subsequent bacterial colonization. The presence of pathogens, particularly opportunistic organisms like Pseudomonas aeruginosa or Haemophilus influenzae, triggers a persistent inflammatory response, attracting neutrophils and other inflammatory cells to the airway. These cells release proteases, such as neutrophil elastase, and reactive oxygen species, which cause further damage to the bronchial elastic tissue and smooth muscle. This destruction leads to airway remodeling, wall thickening, and the characteristic dilation, which in turn further compromises mucus clearance, perpetuating the cycle of infection and inflammation. ## Clinical Presentation The clinical hallmark of bronchiectasis is a chronic, productive cough, often present for months or years. The sputum produced is typically voluminous, purulent, and may be foul-smelling, particularly in cases where anaerobic organisms are present. Many patients also experience significant dyspnea on exertion, which can progress as lung function declines. Hemoptysis is another common symptom, ranging from blood-streaked sputum to massive, life-threatening hemorrhage caused by the hypertrophy of bronchial arteries under high pressure within the damaged airway walls. Pleuritic chest pain may occur during acute exacerbations or due to secondary pleurisy. On physical examination, clinicians may note inspiratory crackles, wheezing, and in advanced or chronic cases, digital clubbing. Fatigue, weight loss, and exercise intolerance are also frequently reported, reflecting the systemic burden of chronic inflammation. ## Diagnostic Criteria The definitive diagnosis of bronchiectasis is established through High-Resolution Computed Tomography (HRCT) of the chest. Classic radiological findings include the "signet ring sign," where the internal diameter of the bronchus is larger than its accompanying pulmonary artery, and a lack of normal bronchial tapering as the airways extend toward the lung periphery. Other findings include bronchial wall thickening, mucus plugging, and "tram-track" opacities representing thickened bronchial walls. Pulmonary function testing (PFT) often reveals an obstructive pattern, although restrictive or mixed patterns can occur in advanced disease with parenchymal scarring. A comprehensive diagnostic workup is essential to identify underlying causes, including sweat chloride testing for cystic fibrosis, immunoglobulin levels to rule out hypogammaglobulinemia, alpha-1 antitrypsin levels, and screening for primary ciliary dyskinesia or Allergic Bronchopulmonary Aspergillosis (ABPA). ## Standard of Care The management of bronchiectasis focuses on breaking the "vicious cycle" by improving airway clearance and controlling infection. Daily airway clearance techniques (ACT), such as chest physiotherapy, oscillatory positive expiratory pressure (PEP) devices, or active cycle of breathing techniques, are fundamental to the mobilization of secretions. Inhaled hypertonic saline may be utilized to assist with mucus hydration and improve clearance efficiency. Acute exacerbations are treated with targeted antibiotic therapy based on sputum cultures. For patients with frequent exacerbations (three or more per year), long-term macrolide therapy may be considered for its anti-inflammatory and immunomodulatory properties rather than just its antibacterial effects. Pulmonary rehabilitation is strongly recommended to improve exercise tolerance and quality of life. In rare cases of localized disease refractory to medical management, surgical resection may be considered. Regular vaccinations against influenza and pneumococcus are crucial preventive measures to reduce the frequency of exacerbations.